Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- GE Healthcare Integrates Two Subsidiaries to Create GE Healthcare Japan
August 24, 2009
- AZ, Astellas to Copromote Symbicort in Japan
August 24, 2009
- SELF-MEDICATION NEWS IN BRIEF
August 24, 2009
- Daiichi Sankyo, Eli Lilly Launch Effient in the US
August 24, 2009
- JACDS Promotes Class 1 OTC Drugs to Increase Sales by 50%
August 24, 2009
- DSP to File NDA for Lurasidone in US in 1st Half of 2010
August 24, 2009
- Emergency Delivery Rates Achieve Goal at 83% in FY2008
August 24, 2009
- Zeria to Acquire Tillotts
August 24, 2009
- R&D NEWS IN BRIEF
August 24, 2009
- Cravit Tab 500 mg Prevents Emergence of Resistant Organisms: Daiichi Sankyo
August 24, 2009
- REGULATORY NEWS IN BRIEF
August 24, 2009
- Kowa's Livalo Approved in US
August 24, 2009
- 8 Prefectures to Prepare Lists of Generics Stocked by Regional Pharmacies
August 10, 2009
- Eisai Licenses Drug-Eluting Bead Products from Biocompatibles
August 10, 2009
- JPMA to Propose Fee-for-Service for Clinical Trials
August 10, 2009
- 4 Cases of Incomplete Artificial Ventilator Connections Reported
August 10, 2009
- R&D NEWS IN BRIEF
August 10, 2009
- Clozaril for Treatment-Resistant Schizophrenia: Novartis
August 10, 2009
- Market for Class 1 OTC Drugs Should Expand in a Few Years: Mr Tokita
August 10, 2009
- Kowas Livalo Approved in US
August 10, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…